Spinnaker Trust Has $934,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Spinnaker Trust cut its position in Becton, Dickinson and Company (NYSE:BDX) by 9.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,115 shares of the medical instruments supplier’s stock after selling 435 shares during the period. Spinnaker Trust’s holdings in Becton, Dickinson and Company were worth $934,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Tompkins Financial Corp raised its holdings in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 46 shares during the period. Radnor Capital Management LLC raised its holdings in Becton, Dickinson and Company by 1.7% in the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock worth $708,000 after purchasing an additional 48 shares during the period. Wesbanco Bank Inc. raised its holdings in Becton, Dickinson and Company by 1.9% in the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock worth $580,000 after purchasing an additional 48 shares during the period. Umpqua Bank raised its holdings in Becton, Dickinson and Company by 1.8% in the third quarter. Umpqua Bank now owns 2,738 shares of the medical instruments supplier’s stock worth $660,000 after purchasing an additional 49 shares during the period. Finally, Americana Partners LLC raised its holdings in Becton, Dickinson and Company by 3.5% in the third quarter. Americana Partners LLC now owns 1,468 shares of the medical instruments supplier’s stock worth $354,000 after purchasing an additional 50 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Becton, Dickinson and Company

In related news, EVP David Shan sold 500 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the transaction, the executive vice president now owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roland Goette sold 638 shares of Becton, Dickinson and Company stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. This trade represents a 4.29 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,544 shares of company stock valued at $2,370,309. Corporate insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the topic of several analyst reports. Piper Sandler increased their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, Barclays raised their price objective on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Buy” and an average price target of $278.29.

Becton, Dickinson and Company Trading Down 0.1 %

Shares of NYSE:BDX opened at $224.89 on Friday. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99. The company has a quick ratio of 0.74, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The company’s fifty day simple moving average is $232.50 and its 200 day simple moving average is $233.82. The firm has a market cap of $65.22 billion, a price-to-earnings ratio of 37.36, a PEG ratio of 1.65 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.85%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 69.10%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.